CompletedPhase 4

Efficacy and Safety of Eupasidin-s Tab.(EUPASIDIN-S) in Gastritis Patients

South Korea230 participantsStarted 2014-08

Plain-language summary

The purpose of this study is evaluate the Efficacy and Safety of EUPASIDIN-S Tab. in Gastritis Patients.

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Age is 19 years old and over, men or women
✓. Patients diagnosed with acute or chronic gastritis by gastroscopy and need a treatment for gastritis symptoms
✓. Patients with one or more erosions found by gastroscopy
✓. Patients who voluntarily signed written informed consent may participate in the study

✕. Patients with peptic ulcer and gastroesophageal reflux disease
✕. Patients with Gastrointestinal malignant tumor or surgery related to stomach resection
✕. Patients with thromboembolism and coagulation disorder
✕. Patients with significant cardiovascular, pulmonary, heptic, renal primary disease
✕. Patients with abnormal laboratory result at screening
✕. Patients administered with H2 receptor antagonists, proton pump inhibitors, muscarine receptor antagonists, other gastiritis treatment drug, protective factor builder, non-steroid anti-inflammatory drugs prior to study in 2 weeks
✕. History of allergic reaction to the investigational product
✕. Women either pregnant, breast feeding or possible to pregnant without contraceptive method

cure rate of erosion

Timeframe: 2 weeks

NCT IDNCT02356679

SponsorChong Kun Dang Pharmaceutical

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-06